Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Research & Development (2020 - 2025)

Historic Research & Development for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $43.0 million.

  • Mirum Pharmaceuticals' Research & Development rose 3547.78% to $43.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $179.1 million, marking a year-over-year increase of 4042.53%. This contributed to the annual value of $140.6 million for FY2024, which is 3705.43% up from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Research & Development stood at $43.0 million, which was up 3547.78% from $46.1 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Research & Development registered a high of $46.1 million during Q2 2025, and its lowest value of $22.0 million during Q2 2023.
  • Its 5-year average for Research & Development is $32.5 million, with a median of $31.1 million in 2022.
  • Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 11991.93% in 2021, then plummeted by 3683.33% in 2022.
  • Over the past 5 years, Mirum Pharmaceuticals' Research & Development (Quarter) stood at $27.8 million in 2021, then grew by 11.99% to $31.1 million in 2022, then dropped by 0.55% to $30.9 million in 2023, then skyrocketed by 42.32% to $44.0 million in 2024, then dropped by 2.42% to $43.0 million in 2025.
  • Its Research & Development was $43.0 million in Q3 2025, compared to $46.1 million in Q2 2025 and $46.0 million in Q1 2025.